New Insights into Inflammation in Atherosclerosis

Abstract

In this mini-review recent developments in the pathogenesis, pathophysiology, biomarkers and therapeutics in residual inflammation of atherosclerosis are discussed. New cellular pathways are discovered raise new interest in old therapeutics as colchicine and niacin. Biomarker studies call for more specific and sensitive markers. The recent CANTOS trial provided clinicians evidence that directly targeting inflammation by canakinumab is beneficial for the secondary prevention of cardiovascular disease. Whole genome and exome studies will lead to the discovery of new cellular pathways and treatments of residual atherosclerotic inflammation.

Autoimmune Buerger’s Disease Joining Polymyalgia Rheumatica: A Case Report

“…Severe allergic rhinitis presented 20 years earlier. Tobacco, also named as a putative antigen in the residual inflammation of atherosclerosis [5] has been present 50 years before Buerger's diagnosis. Genetic predisposition has been present 62 years in this patient.…”